

Special Issue

New Insights to Cancer Therapy Resistance

Message from the Guest Editor

In recent decades, considerable advances have been made in understanding tumor-driving mechanisms, which have fueled the development of novel therapeutic approaches benefitting many patients. The major progress is represented by the further development of immunotherapy and targeted therapy with small molecules, e.g., KRASG12C-specific inhibitors. Despite this considerable progress, cancer is an evolving disease, and resistance develops almost immediately and is found in clinics. The current Special Issue addresses the emerging questions of how these forms of resistance occur and reveal the underlying mechanisms. The collation of more detailed knowledge obtained from experts of different cancer research fields addressing the relationships of molecular mechanisms and resistances occurring in clinics offers a great opportunity to promote an improved understanding and the development of resistance-overcoming approaches.

Guest Editor

Dr. Sebastian Oeck

West German Cancer Center, Department of Medical Oncology,
University Hospital Essen, University of Duisburg-Essen, 45147 Essen,
Germany

Deadline for manuscript submissions

closed (29 February 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/138779

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)